Table 1.

Cohort summary and randomization group comparison of patients returning at 6-weeks.

	Lidocaine (N=211)	Placebo (N=209)
Age, years (SD)	67 (9.1)	67 (9.5)
Gender, N (% Female)	60 (28.4)	49 (23.4)
Race, N (% Caucasian)	200 (94.8)	186 (89.0)
Weight, kg (SD)	83.8 (16.5)	82.8 (17.4)
History of hypertension, N (%)	124 (59.0)	128 (61.2)
Previous myocardial infarction, N (%)	31 (14.7)	38 (18.2)
History of atrial fibrillation, N (%)	56 (26.5)	50 (23.9)
History of neurological incident	23 (10.9)	19 (9.1)
Ejection fraction (Q1, Q3)	55 (50, 55)	55 (55, 60)
Ejection fraction < 30%, N (%)	2 (0.9)	5 (2.4)
Years of education (Q1, Q3)	15 (12, 16)	16 (13, 17)
Preoperative statin use, N (%)	121 (57.3)	131 (62.7)
Preoperative platelet inhibitor use, N (%)	149 (70.6)	150 (71.8)
Preoperative cognitive index (SD)*	0.02 (0.7)	0.01 (0.7)
Lidocaine level at baseline, mcg/mL (SD) +	0.09 (0.3)	0.06 (0.2)
Baseline CES-D (SD) *	9.0 (6.7)	8.4 (6.8)
Baseline STAI (SD) *	36.7 (11.4)	36.2 (10.7)
Surgical Procedure, N (%)
CABG	61 (28.9)	62 (29.7)
CABG + Valve	21 (10.0)	23 (11.0)
Valve	129 (61.1)	124 (59.3)
Previous CABG/Valve Surgery, N (%)	24 (11.4)	24 (11.5)
CPB time, min (Q1, Q3)	157 (127, 198)	166 (124, 214)
Cross-clamp time, min (Q1, Q3)	100 (74, 120)	101 (67, 121)
Number of bypass vessels (Q1, Q3) ‡	3 (2, 4)	3 (2, 4)

^*Missing data imputed using SRCWARE and combined statistics presented here were generated using SAS proc MIANALYZE.

⁺Baseline values are non-zero numbers because the analytical measurement range of the lidocaine assay is 0.6 – 8.0 mcg/mL, thus values below this linear range (including 0 values) may be reported as <0.6 mcg/mL.

^‡Among those that received grafts.

Data are reported as mean (SD) or median (Q1, Q3) as appropriate.

CES-D: Center for Epidemiologic Studies – Depression Scale, STAI: State Trait Anxiety Inventory, CPB: cardiopulmonary bypass.